DexCom — May 1, 2025 release

The reduction relative to prior guidance primarily results from incremental costs related to near-term supply dynamics that were previously disclosed as the company reestablishes optimal finished goods inventory levels. • Non-GAAP Operating Margin of approximately 21% • Adjusted EBITDA Margin of approximately 30% The company also announced a $750 million share repurchase program in conjunction with first quarter results. First Quarter 2025 Financial Results Revenue: In the first quarter of 2025, worldwide revenue grew 12% to $1.036 billion on a reported basis, up from $921.0 million in the first quarter of 2024. Gross Profit: GAAP gross profit totaled $589.0 million or 56.9% of revenue for the first quarter of 2025, compared to $561.9 million or 61.0% of revenue in the first quarter of 2024. Non-GAAP gross profit* totaled $596.2 million or 57.5% of reported revenue for the first quarter of 2025, compared to $569.1 million or 61.8% of reported revenue in the first quarter of 2024. 1 First quarter 2025 organic revenue was $1.046 billion and excludes $9.9 million of foreign exchange impact. First quarter 2024 reported revenue included $2.8 million of non-CGM revenue subsequently divested in the following twelve months. Operating Income: GAAP operating income for the first quarter of 2025 was $133.7 million or 12.9% of revenue, compared to GAAP operating income of $101.1 million or 11.0% of revenue for the first quarter of 2024. Non-GAAP operating income* for the first quarter of 2025 was $143